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1. Introduction
The severest hypertensive states pose an immediate threat to life. To be able to manage these
situations, physicians need well-defined recommendations; however, as with some other
emergencies, only few evidence-based strategies have been developed to date.[1] As random‐
ized, placebo-controlled trials are very difficult to design and conduct, most guidelines and
recommendations are based just on experience. The recommendations and opinions in the
present chapter draw mainly from national, European, and American guidelines for the
treatment of hypertension, and on guidelines of professional societies such as the European
Stroke Organisation as well as the experience gained in the author´s health-care center.[2-6]
2. Terminology
The terminology used for severe hypertensive states is not fully consistent, clear, and system‐
atic. Severe hypertension-associated states can be divided into hypertensive emergencies and
hypertensive urgencies under the general title a hypertensive crisis.
Hypertensive emergencies (HE) referring to more severe hypertensive states are defined as
an acute, life-threatening states due to a sudden marked rise in blood pressure (BP) resulting
in complaints and damage to the structure of some organs. [2-6] High BP leads to the devel‐
opment of acute problems and presentation of organ damage when reaching systolic and
diastolic BP usually greater than 220 mm Hg and 120 mm Hg, respectively. However, in
individuals so far normotensive, a hypertension may lead to a critical condition such as
eclampsia already at a systolic BP of 170 mm Hg. The severity of the condition is dependent
mainly on organ damage, not solely on the level of BP. The immediately threatened vital organs
include the central nervous system and the cardiovascular system. Any damage to other organs
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(particularly the kidneys and eyes) is essentially always of primarily vascular etiology; hence,
these organs are referred to as target ones. It is reasonable to refer to manifestation of damage
since milder damage is often likely to go undetected. Importantly, damage to the central
nervous and cardiovascular systems may pose an immediate threat to life. However, even
manifestation of damage to another organ is associated with an increased risk of sudden
damage to organs performing vital functions.[2-6]
According to the guidelines of the European Society of Hypertension (ESH) and the European
Society of Cardiology (ESC), hypertensive emergencies comprise: hypertensive encephalop‐
athy, hypertension with heart failure (including acute so-colled flash pulmonary oedema
conditioned by sudden increase in BP), hypertension in acute coronary syndromes, hyperten‐
sion in aortic dissection, hypertension in intracranial hemorrhage and ischemic stroke,
sympathetic crises due to pheochromocytoma or an abuse of so-called recreational drugs
(amphetamine, LSD, cocaine, ecstasy/MDMA etc.), perioperative hypertension, eclampsia/
severe pre-eclampsia and acute renal failure in hypertension (Table 1). Some listed HE are not
accompanied by organ damage but the instability of the circulatory status and threats to the
structure and function of organs belongs them between HE. In the European guidelines, the
list of situations classified as HE is preceded by the word „primarily“[4]; hence the item is open
for inclusion of other conditions. The current definition also seeks to avoid taking a clear
position on the causality of hypertension and organ dysfunction as the degree of causality is
frequently unclear.
Hypertensive ugencies should be characterized by complaints yet without manifest organ
damage, with BP greater than 180/110 mmHg. These states include accelerated and malignant
hypertension, postoperative hypertension, and hypertension in chronic heart failure. In
addition to high BP (diastolic BP typically greater than 140 mm Hg), accelerated hyperten‐
sion is characterized by vascular injury presenting with retinal hemorrhage and exudate
formation. The malignant hypertension is more over associated with papilledema and/or
renal injury and encephalopathy, manifestations of organ damage characteristic for HE. [2-6]
From this perspective, it seems questionable resolution HE and hypertensive urgencies. The
most recent joint ESH a ESC guidelines no longer list the term urgent hypertensive state as it
usually does not require specific therapeutic strategies and hospitalization in the intensive care
unit (ICU). Management of it is based on stepping up standard therapy with oral medications.
Only in cases where it fails or in specific cases not allowing oral administration is parenteral
treatment used.[4]
3. Etiology and prevalence of hypertensive emergencies
A role in the etiology of emergent hypertensive states is most often played by inadequate
treatment of known hypertension and therapy discontinuation. [2,3,7] Pathophysiological
mechanisms include a sudden rise in peripheral vascular resistance and systemic vasocon‐
striction due to activation of the renin-angiontension-aldosterone system, sympathoadrenal
system, endothelin, exogenous factors, injury to the central nervous system, bleeding, tumor
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or ischemia, or perioperative stress. Except for conditions associated with renal failure,
increased natriuresis and vasoconstriction result in reduced vascular filling. This can be
effectively managed by afterload reduction; diuretic use is less effective. Hypertensive
encephalopathy develops due to cerebral edema, which forms once the autoregulatory
capacity of blood flow through brain arteries has been exceeded. The autoregulatory threshold
is typically a mean BP of 140 mm Hg; however, the value may be higher in protracted severe
hypertension. Other factors contributing to the development of edema include both hydro‐
static mechanisms and changes in the vascular wall.[8]
The exact prevalence of severe hypertensive states is not known. These states occur more
frequently in patients with nephrogenic hypertension and hyperaldosteronism. An emergent
hypertensive status develops in about 1% of hypertensives during their lifetime.[9] An earlier
US study reported about 8% and 16% of patients presenting at medical part of the emergency
department with emergent and urgent hypertensive states, respectively.[10] In the experience
of the author of this chapter, about 5% of patients admitted to the Intensive Cardiac Care Unit
are diagnosed to have states somehow related to severe hypertension.
4. Clinical picture
The most frequent complaints accompanying HE include chest pain (27%), dyspnea (22%),
headache (22%), epistaxis (17%), weakness and psychomotorical agitation (10%), whereas
other authors list headache (49%) and weakness (22%) as the most frequently experienced
problems.[5,8] Other complaints include palpitations, nausea, vomiting, anxiety and feeling
of illness. Organ damage manifests itself most often as cerebral stroke (24%), lung edema (23%),
neurological deficit (21%), and hypertensive encephalopathy (16%). Cerebral hemorrhage is
diagnosed as little as 4.5% of cases (Tab. 2).[10] Retinal hemorrhage, exudates, and papilledema
can also occur, indicating damage to other organs. These lesions do not subside until after
several weeks since BP reduction. Oliguria, hyperazotemia, and proteinuria signal renal injury.
Patients complaining of concomitant chest pain or other discomfort or with EKG-documented
ST-segment depressions and a mild increase in cardiac troponins in serum can be diagnosed,
according to the Universal definition of myocardial infarction, as type 2 myocardial infarction
due to an imbalance between oxygen demand and supply.[11]
5. Examinations
Given the possibility of coarctation, atheorsclerosis of brachial arteries or, possibly, aortic
dissection, BP should be measured on both arms. Measurement of BP in the lower limbs will
rule out stenosis of arteries in both arms, a rare occurence. Blood pressure is measured using
a properly-sized cuff to match the limb circumference. During subsequent managements in
the ICU, BP is commonly measured noninvasively at intervals of 5 minutes to 1 hour depending
on the severity of organ damage and BP level and instability. Only in cases of persisting
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instability of BP and its difficult control, or with conditions such as dissecting aneurysm
requiring controlled hypotension, is it necessary to insert an arterial line. The cannula should
be preferably inserted after a reduction of BP by initial therapy in some compressible brachial
artery. An integral part of physical examination is neurological assessment to guide therapy.
Basic biochemical tests including plasma concentration of minerals, urea, creatinine, markers
of myocardial necrosis, natriuretic peptides, liver tests (to determine elimination of drugs),
urinalysis (albuminuria, hematuria, crystaluria, etc.), and blood count should be done
immediately. Additional examinations include EKG, chest x-ray, and fundoscopy. Echocar‐
diography is performed in the context of hypertension primarily to assess the presence of
myocardial dysfunction, muscle hypertrophy or, possibly, to roule out dissection of the aorta.
Patient diagnosed to have focal neurological deficit and encephalopathy require a brain CT.
Additional examinations are performed based on the patient´s current status.
6. Management
Management of HE should be instituted immediately and continued in ICU. Therapy during
transportation to the ICU is of course limited espetially by the possibilities of BP measurement
as well as by continuous dousing of IV medication.
The goal of treatment is to reduce BP and thus to prevent target organ damage and threat of
life. However, very high BP must not be reduced very quickly. Too rapid and large BP
reduction could be as dangerous and harmful as high BP. Blood pressure should be reduced
by only 20-25% of baseline value over the first hours or until reaching levels 150-160/100-110
mm Hg. Alternatively, it is recommended to decrease mean BP to below 110-115 mm Hg within
30-60 minutes and, possibly, continue depending on the response and, most importantly, on
how the patient tolerates the reduction. An abrupt fall in BP may-primarily in elderly patients
with coronary and cerebrovascular atherosclerosis-impair organ perfusion, possibly resulting
in acute renal failure, ischemic heart and cerebral events, renal artery occlusion and, eventu‐
ally, acute blindness. However, in many cases, it is impossible to achieve a steady reduction
of BP as recommended, particularly in settings where invasive monitoring is unavailable. A
frequent occurrence is a rapid fall of an initially resistant high BP once contributing factors
such as fear, uneasines and pain have disappeared. Achievement of the target BP for the
chronic treatment is supposed within 1-2 days.[2-6]
The drugs to be used should have a short half-time of action but a rapid onset of action. They
should be administered intravenously. When planning to use a combination of such agents, it
is reasonable to have several venous access sites allowing for their separate administration.
This often requires the insertion of a central venous line. Some agents such as nimodipine
should only be administered via a central venous catheter. On the other hand, any inadvertent
puncture of an artery in an effort to cannulate a central vein of a patient with poorly controlled
high BP carries the risk of major bleeding.[2-6]
Hypertensive urgencies can usually be managed by intensification of their oral therapy or
its complementation. Parenteral therapy is not started unless oral therapy has failed or is
Evidence-based Strategies in Herbal Medicine, Psychiatric Disorders and Emergency Medicine56
not accepted. Stay at ICU is not necessary. According to US authors, therapy can even be
administered on an outpatient basis with intensive patient monitoring over the first days
of therapy. [2,10]
7. Drugs for IV therapy of severe hypertension
The agents currently available for parenteral therapy include nitrates, urapidil, diuretics,
angiotensin-converting blockers, calcium-channel blockers, beta-blockers, alpha-blockers,
combined alpha-and beta-blockers, clonidine and fenoldopam.(Tab. 3) [2,3,6]
Nitrates (isosorbide dinitrateand glycerol-trinitrate) can be the drugs of first choice in almost
all conditions. They can be combined with most of the other hypertensive classes and are a
reasonable option for pre-hospital initiation of therapy, with a rapid onset of effect within 2-5
minutes to subside within 5-10 minutes. Nitrates are applied as continuous infusion at a rate
of 0.5-10 mg/h. At higher doses veno-as well as arteriodilation is present. If given at high doses,
the antihypertensive effect is usually not incremental, yet the risk of headache is increased. As
the patient becomes tolerant to continuous infusion, nitrates should be stopped discontinued
after 2 days.[12] Sublingual nitrate administration may result in too rapid fall of BP; the effect
is short-term, hence this use is not reasonable.
Sodium nitroprusside is one of the most effective drugs with an almost immediate onset of
effect and a short half-life, with the BP reduction resolving within 2-3 minutes. Infusion therapy
is started at 0.2 μg/ kg /min. The rate of infusion is every 3-5 minutes doubled to achieve the
target BP. The speed of the application usually does not exceed 10 μg/kg/min. The mechanism
of its action is vasodilation; however, unlike nitrates, it exerts a more marked effect on
arterioles. As a major drawback of sodium nitroprusside is its photosensitivity. It should be
infused via dark-color sets, with the infusion bottle covered with a light-tight material. Infusion
at a higher rate for 2-3 days, particularly in patients with renal failure, is associated with the
risk of intoxication with thiocyanate, a sodium nitroprusside metabolite, manifesting itself
with confusion, nausea, and acidosis. Thiocyanate intoxication can be prevented by monitoring
its levels. Concentration greater than 10 mg/100 ml is toxic. Alternatively, toxicity can be
reduced by thiosulfate infusion, continuous infusion of 10% sodium thiosulfate in a volume
ratio of 10:1 (nitroprusside : thiosulfate).[13]
Urapidil hydrochloride is an antagonist of peripheral alpha1-postsynaptic receptors; animal
studies have shown it is also an antagonist of central 5-hydroxytryptamine-1A receptors. It
has been shown to decrease particularly peripheral vascular resistance withe the resultant
decreas both preload and afterload. It has been associated with marked selective renal and
pulmonary vasodilation. Unlike other vasodilators, it does not induce appreciable tachycardia,
likely due to central modulation of cardiovascular centers via 5-hydroxytryptamin receptores.
Its other effects include mild β1-blockade. Urapidil decreases systolic and diastolic BP in a
balanced manner. The onset of its effect is virtually immediate, peaking within 2-5 minutes.
Its antihypertensive effect subsides completely within 4 hours at most. Regarding its use in
stroke, it should be noted that, unlike other antihypertensives, urapidil does not exacerbate
Hypertensive Emergencies
http://dx.doi.org/10.5772/59005
57
cerebral edema and intracranial pressure. Urapidil is extensively metabolized (50-70%) in the
liver, with 15-50 % of the drug excreted through the kidneys. Side effects are rather rare and
mild. The most frequent ones include tachycardia, sweating, chest discomfort, dyspnea, and
weakness. If given at higher doses, urapidil has a sedative action. Literary data suggest that
its antihypertensive effect is similar to that of enalaprilat, nitroprusside, nifedipine, and
dihydralazine. Resistance to urapidil occurs more rarely with with enalaprilate and nifedipine.
As a standard policy, therapy with urapidil is initiated with a bolus followed immediately by
continuous infusion. It is recommended to give a 10-50 mg bolus over 20 seconds depending
on the BP level and clinical status. If there is a sufficient decrease in BP within 5 minutes of
bolus administration, continuous therapy can be initiated. In the event of an inadequate effect
of the first bolus, especially when rapid BP control is needed, additional boluses should be
administered with patient status to be re-assessed at a 5-minute interval. While repeat bolus
administration until achieving target BP with subsequent maintenance therapy provide for
the quickest BP normalization, the total dose of initial boluses should preferably not exceed
50 mg because of the risk of a sudden severe fall of BP. A dose of 100 mg is only an alternative
for very severe resistant hypertension with signs of organ damage. By contrast, in patients
raising concern of a major fall in BP and a less emergent status, therapy can be initiated directly
with continuous i.v. infusion at a rate of 120 mg/h without initial bolus administration with a
subsequent decrease in the infusion rate once the BP has decreased. It is recommended to
continue with maintenance therapy at a rate of 2–10 mg/h depending on the patient´s status
and their BP level. The maximum recommended rate for long-term administration is 30
mg/h. The maximum recommended therapy duration 7 days based primarily on toxicology
studies not exceeding the above period of time. Longer administration requires closer moni‐
toring of the patient´s status. In the presence of liver or renal failure, it is also recommended
only to perform closer hemodynamic monitoring without dose reduction. Given the risk of
severe hypotension, combinations of urapidil with another alpha-blocker are contraindicated.
Overdose with urapidil or development of side effects can usually be simply managed by dose
reduction or therapy discontinuation. In persistent moderate hypotension, the procedure of
choice is, of course, volume expansion or, possibly, IV catecholamine administration.
In the case of perioperative hypertension, the recommendation is to initiate therapy with a 25
mg bolus; if effective within 2 minutes of the initial bolus, the patient can be switched to
maintenance therapy. The recommended dose of urapidil for maintenance perioperative
therapy is 60-180 mg/hour. No data regarding gestational hypertension and urapidil excretion
to breast milk are currently available.[14-19]
As urapidil has not yet been approved by the US Food and Drug Administration (FDA), it is
simply not mentioned in a number of texts published in the USA.
Clonidine  is  a  centrally-acting  drug.  It  acts  primarily  via  alpha2-receptors  to  produce
protracted vasodilation. Its plasma half-life is in the range of 12 hours. Clonidine could be
administered IV as a very slow 150 μg bolus (over 10-15 minutes) or infusion at rate 1-2
μg/kg/min. Maximal daily dose is 750 μg. At present, its use is reserved for combinations
in  resistant  hypertension and situations  requiring sedative  effect.  Because  of  the  risk  of
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potential  respiratory  center  inhibition,  it  can  be  used  with  advantage  in  patients  with
mechanical ventilation.[20,21]
Fenoldopam mesylate is a selective D1 dopamin receptor agonist with a half-time of
elimination as short as 5 minutes. It causes renal, mesenteric, and coronary arteriodilation
while also increasing sodium excretion. Hypotensive efficacy is similar to that of sodium
nitroprusside. As a side effect, it produces a tendency to developing tachycardia. However, its
co-administration with betablockers may be extremely harmful. Usual initial dosage is 0.1–0.3
μg/kg/min. To achieve desired therapeutic effect, may titrate dosage upward or downward in
increments of 0.05–0.1 μg /kg/min.[22,23]
Furosemide is a diuretic suitable for emergent situations. Needless to say, its use is appropriate
in heart failure and conditions associated with edema formation. As a drug of first choice it is
little effective. Ahigh BP induces natriuresis, which, together with frequently concomitant
nausea/vomiting, results in fluid depletion and need for hydration rather than diuretic use.
Not infrequently is BP reduction seen following saline administration.
Enalaprilate is the only angiotensin-converting enzyme available in injectable form. Its major
advantage is its favorable effect on cerebral vascular autoregulation. When administered i.v.,
its onset of action occurs within 15 minutes, with its peak effect expected after 1-4 hours.
Regrettably, the strength and duration of its action are variable lasting as it may 6 but, also 24
hours. Enaprilate is excreted via the kidney. Its dose should be adjusted in patients with renal
insufficiency. Contraindications to enaprilate use are identical with those applicable to other
angiotensin-converting enzyme inhibitors. As a result, enaprilate is used mostly as a drug of
second or third choice in resistant hypertension on the assumption it will not induce undesir‐
able hypotension. The risk of hypotension is particularly high in patients experiencing
dehydration. Enalapril is administered as a 0.625 to 1.25 mg bolus, most often at a 6-hour
interval depending on the effect. The body of experience with continuous administration is
fairly limited.[24]
In outpatient practice, and as a first-aid measure, crushing of a tablet of the short-acting
angiotensin-converting enzyme inhibitor captopril at a dose of 25-50 mg may occasionally be
helpful. However, in really serious situations with uncertainty regarding future course
including the state of consciousness, oral captopril should not be administered.
Calcium-channel blockers have proved effective, particularly in the management and
prevention of vasopasms in subarachnoidal hemorrhage. By contrast, concerns have been
voiced about their use in ischemic stroke where they may exacerbate collateral cerebral edema.
Favorable experience has been obtained with the dihydropyridine-type drugs nicardipine and
nimodipine. A drawback of nimodipine is has to be infused via a central venous catheter.
Usual infusion rate is 0.5-2.0 mg/h. It is used preferably only in cases of subarachnoidal
hemorrhage indicated for neurosurgery. In the event of surgical intervention during treatment,
administration of nimodipine should be continued for at least five days. [25] Currently the
most promising agent is the novel ultrashort-acting agent clevidipine inducing selective
arteriolar dilation including the coronary bed, with onset of action occurring within 2-4
minutes and lasting 5-15 minutes. Dose range between 2 and 16 mg/h. Like nitroprusside or
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calcium-channel blockers clevidipine produce a marked decrease in BP with a mild rise in
heart rate and cardiac output. Clevidipine provided in the study ECLIPSE better blood
pressure control compared to nitroglycerine and nitroprusside.[26-28] Less experience in
emergent hypertensive stats is available with continuous administration of verapamil slowing
down heart rate and exerting a somewhat negative inotropic effect. Its use has been suggested
in hypertensive states associated with tachycardia at total dose up to 100 mg/day.[29]
Betablockers are the drugs of choice in hypertension and tachycardia. They are particular‐
ly advantageous in combination with urapidil or nitroprusside. Betablockers are one of the
few classes of drugs appropriate for use in patients with severe hypertension and ische‐
mic stroke. They are traditionally used in the treatment of dissecting aneurysms as they
are believed to reduce pulse pressure thereby decreasing aortic wall stress; however, their
effect  on Dp/Dt has been recently challenged.  Betablockers are recommended for use in
intraoperative  hypertension.  Particularly  esmolol,  highly  beta1-selective  and  ultra-short
acting drug with peak effect after administration of 500 mg/kg bolus followed by continu‐
ous i.v.  administration reached during 5 minutes  and resolving within 10-30 minutes is
recommended in HE. The dose is up-titrated at a 5-minute interval with or without boluses.
Continuous  dose  range  between  25  and  300  μg/kg/min.  [30]  Metoprolol  in  continuous
infusion at  a  rate  1-5  mg/h could be  also  effective  but  with  longer  hilf-time and lower
selectivity  compare  to  esmolol.  Boluses  of  2.5-5  mg administered  one  to  three  times  as
needed to achieve goal are also frequently used.[31]
Labetalol is both a selective alpha1-blocker and predominantly a non-selective beta-blocker.
Treatment is initiated depending on its effect with 5-160 mg boluses administered repeatedly
at 2-10 minutes to a maximum dose of 300 mg. Labetalol can also be administered continuously
at a rate 2 mg/minutes up to a total dose of 300 mg/24 hours. The effect sets in within 5-10
minutes and resolves within 2-6 hours. A traditional indication-apparently based, in particular,
on the absence of adverse experience-is management of pre-eclampsia/eclampsia. It is also the
drug of choice in other situations, except those contraindicated to beta-blocker use.[32] In the
USA, labetalol is the drug most often used in the treatment of HE.
Alpha-blockerphentolamine is indicated espetially for the control of hypertensive episodes
that may occur in a patient with pheochromocytoma as a result of stress or manipulation
during preoperative preparation and surgical excision. Boluse dose of 5 mg should be applied
fast with BP measurements in 1 minute’s intervals during first minutes after administration.
Repeated administration could be necessary during surgery.[33]
8. Management in specific situations
The choice of individual classes of drugs depends on the underlying disease resulting in HE
or it is associated with. To date, only few randomized studies have been conducted evaluating
treatment of HE and almost no studies designed for head-to-head comparison of various
drugs.[1]
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Ischemic stroke usually results in an increase in BP for 1-4 days. Drug therapy of this type of
hypertension is associated with the risk of impairing vascular autoregulation with a subse‐
quent decrease in blood flow in the vicinity of the ischemic focus.[35,36] Besides, patients are
also increasingly susceptible to an abrupt fall in BP. The benefit of BP reduction in the acute
stroke has not been documented except for situations with a diastolic BP > 130 mm Hg
conclusively associated with progressive damage to brain structures. It is recommended not
to decrease BP until it levels rise above 200-210/120 mmHg. Within the first hours after
hospitalisation, BP should be decreased by 10% of the baseline value. The target BP is below
180/105 mmHg. As BP increases, the risk of secondary bleeding is also likely to increase,
apparently not a rare occurrence even without marked hypertension. In patients indicated for
thrombolytic therapy it is recommended to reduce BP below 180/110 mm Hg.[35,36] Substan‐
tial reduction in BP may be indicated only by the simultaneous occurrence of diseases such as
heart failure, acute coronary syndrome or aortic dissection. Fast but short acting i.v. drugs are
preferred for the accurate titration of the effect. Drugs with side effect of steal phenomenon,
worsening of brain oedema due to brain vasodilator effect are to be excluded. The treatment
is recommended especially with medication such as labetalol and betablockers. A good
experience is with fast and realtively shortly acting urapidil inspite of the risks of the central
sedative effect. Enalaprilat may have a beneficial effect on cerebral vascular autoregulation
but it is associated with the risk of inducing undesirable protracted hypotension.
In hemorrhagic stroke, the recommendation is to reduce BP already at levels 160/110 mm Hg,
with target BP being 140-160/90 mm Hg.[1] No additional BP correction is necessary once
bleeding has been controlled. In the presence of vasospasms, the target BP level is 180-220 mm
Hg once bleeding has been controlled. The drugs used in hemorrhagic stroke are the same as
those indicted for ischemic stroke Moreover dihydropyridine calcium-channel blockers can
also be used for continuous i.v. therapy, particularly in subarachnoidal hemorrage. Even in
the absence of elevated BP, calcium-channel blockers can prevent the development of vaso‐
spams, a frequent occurrence in subarachnoidal hemorrhage.[37]
In hypertensive encephalopathy, therapy can be initiated with a nitrate. Other recommended
agents include parenteral labetalol, esmolol, and enalaprilate. When administering higher
doses of urapidil, one should be aware of its sedative effect carrying the risk of impaired
consciousness. High BP reduction results in a prompt resolution of symptoms such as
confusion, sleepiness to comatose states, seizures or focal and sensory disorders. A typical up
to diagnostic feature of hypertensive encephalopathy is the disappearance of impaired
consciousness after diastolic BP reduction below 100-110 mm Hg. However, it is always critical
to exclude another organic cause of symptoms attributed to hypertensive encephalopathy.[2,6]
In congestive heart failure, treatment is initiated with nitrates and diuretics. The drug of choice
is enalaprilate or, alternatively, urapidil decreasing, in a desirable manner, simultaneously
preload and afterload. In this context, fenoldopam seems to be a most promising drug. An
important part of therapy is sedation. In heart failure, BP should be reduced more aggressively
to levels below 140/90 mm Hg.
Acute coronary syndromes in hypertension are managed with parenteral nitrates combined
with betablockers or, possibly, with urapidil. A critical consideration in these conditions are
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sedation and pain relief. This therapy should precede more aggressive antihypertensive
therapy as a high BP is most often due to pain and anxiety. On the other hand, BP normalization
may contribute to reduction of myocardial load and pain relief.
Acute aortic dissection requires reduction of systolic BP to 100 mm Hg within 20 minutes,
most often using a combination of a nitrate, nitroprusside or urapidil with a betablocker. Even
when dissection is only suspected, systolic BP should be lowered to 120 mm Hg within 20
minutes. [2,6]
In acute renal failure with severe hypertension, the most effective drugs include urapidil,
nitropruside, clonidine, and fenoldopam.[2,6,38] In the presence of hyperhydratio, extracor‐
poreal elimination can be indicated in addition to high-dose furosemide. Aggressive therapy
should be initiated particularly in the presence of a sudden rise of azotemia and so-called
shadows of damaged red blood cells in the urine and dysmorphous red blood cells in urinalysis
in phase contrast imaging. A steady BP reduction is especially important in renal injury.
In pheochromocytome with severe hypertension, an advantageous approach is to initiate
therapy with an isosorbide dinitrate-type nitrate. In more severe states, treatment is based on
a combination of urapidil with a betablocker. Given its predominantly betablocking action,
extra caution should be exercised when using labetalol. The alphablocker phentolamine is
employed primarily in surgical removal of pheochromocytoma. [2,6]
Treatment of hypertension induced by amphetamine or cocaine abuse is guided by principles
similar to those with pheochromocyte. Excessive release of catecholamines has also been
reported. [2,6]
Hypertension induced by other exogenous substances is likely to be associated with vaso‐
constriction and tachycardia, which is why appropriate therapy includes vasodilatators and
drugs with bradycardiac activity. [2,6]
In eclampsia/severe pre-eclampsia, treatment should be started already at BP > 170/110 mm
Hg. Labetalol is the traditionally recommended drug. As with a variety of other conditions,
treatment can be initiated with a nitrate switching the patient to urapidil with a betablocker
in resistant hypertension. Nitroprusside can only be administrated over a short period time.
While the effect of verapamil can also be tested but the drug should not be administered with
MgSO4 commonly given in eclampsia because of the risk of aggregation.[2,6]
In intra-operative hypertension, the preferred drug is the ultrashort-acting betablocker
esmolol. The drugs of choice include nitrates, urapidil, and dihydropyridine-type calcium-
channel blockers. [2,6]
A switchover from parenteral to oral therapy should be undertaken once the patient has
stabilized to make hospitalization as short as possible. It is reasonable to test the efficacy of the
chosen medication for at least 1-3 days in the hospital setting. After discharge, the patient
should be followed-up at intervals ranging from one week to several weeks.
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9. Prognosis
Uncontrolled malignant hypertension results in 90% one-year mortality due to heart failure,
stroke, or renal failure. There are virtually no data from randomized controlled studies
showing how treatment with individual drugs affects mortality and morbidity, and whether
any drug is superior to another one. Introduction of novel ultrashort-acting and well tolerated
drug are expected to provide the greatest benefit in the near future.
Hypertensive encephalopathy
Hypertension with heart failure
Hypertension in acute coronary syndromes
Hypertension in aortic dissection
Hypertension in intracranial hemorrhage
Hypertension in ischemic stroke
Sympathetic crises due to pheochromocytoma
Sympathetic crises after abuse of so-called recreational drugs (amphetamine, LSD, cocaine, ecstasy/MDMA)
Perioperave hypertension
Eclampsia and severe pre-eclampsia
Acute renal failure in hypertension
Table 1. Hypertensive emergencies
Complaints %
Chest pain 27
Dyspnea 22
Headache 22-40
Nosebleed 17
Weakness and psychomotor agitation 10-22
Organ damage
Increase in troponin levels above the diagnostic cut-off for AMI (Type-2 AMI) 38
Stroke 24
Pulmonary edema 23
Neurological deficit 21
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Complaints %
Hypertensive encephalopathy 16
Cerebral hemorrhage 4.5
Table 2. Most common manifestations of emergent and urgent hypertensive states
Nitrates (isosorbid-dinitrate, glycerol-trinitrate)
Mechanism of action: venodilatation, at higher doses arteriodilation
Onset of action: maximal effect within 2-5 minutes
Duration of action: 5-10 minutes
Specific indications: medication of choice in almost all situations, mostly first choice medication, advantageous
especially for heart failure and acute coronary syndromes
Specific contraindications: ischemic stroke
Sodium nitroprusside
Mechanism of action: arterio- as well as venodilation
Onset of action: almost immediate, maximal effect within 2-3 minutes
Duration of action: minutes, circulatory half-life about 2 minutes
Specific indications: particularly resistant hypertension, controlled hypotension
Specific contraindications: liver failure, severe cardiovascular stenotic defects, ischemic stroke
Urapidil hydrochloride
Mechanism of action: vasodilatation (antagonist of peripheral alpha1-postsynaptic receptors, antagonist of central 5-
hydroxytryptamine-1A receptors), mild beta1-blockade
Onset of action: almost immediate, maximal effect within 2-5 minutes
Duration of action: up to 4 hours
Specific indications: sever and resistant hypertension in almost all situations, controlled hypotension
Specific contraindications: no data regarding lactation
Clonidine
Mechanism of action: vasodilatation (centrally acting alpha2-agonist), sedative, analgesic and opioid
properties
Onset of action: almost immediate
Duration of action: plasma half-life is ranging between 10 and 20 hours
Specific indications: for combinations in resistant hypertension and situations requiring sedative effect
Specific contraindications: severe brady-arrhythmias resulting from either sick sinus syndrome or AV block of 2nd or
3rd degree
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Fenoldopam mesylate
Mechanism of action: selective renal dopamine D1 receptor agonist; renal, mesenteric and coronary arteriodilation,
increase of sodium excretion
Onset of action: rapid, most of the antihypertensive effect attained in 15 minutes
Duration of action: quickly reversible, half-life 5-10 minutes
Specific indications: particularly useful in patients with severe hypertension associated with end-organ renal damage
or volume overload
Specific contraindications: administration with beta-blockers
Enalaprilate
Mechanisms of action: angiotensin-converting enzyme, normalization of cerebral vascular autoregulation
Onset of action: within 15 minutes, peak effect after 1-4 hours
Duration of action: 6 - 24 hours
Specific indications: drug of two to third choice in resistant hypertension
Specific contraindication: pregnancy, common contraindications to angiotensin-converting enzyme inhibitors
Nimodipine
Mechanisms of action: calcium-channel blocker with preferential activity on cerebral vessels; increase of cerebral
perfusion, particularly in poorly perfused areas, by arterial dilatation
Onset of action: almost immediate
Duration of action: the half-life is 1.1 - 1.7 hours, the terminal half-life is 5-10 hours
Specific indications: preferably aneurysmal subarachnoidal hemorrhage
Specific contraindication: lack of a central venous catheter
Clevidipin
Mechanisms of action: calcium-channel blocker; selective arteriolodilatation including coronary arteries
Onset of action: within 2–4 min.
Duration of action: 5–15 min.
Specific indications: rapid reduction of BP in the perioperative setting
Specific contraindication: must not be used in patients with defective lipid metabolism accompanied by
hyperlipidemia.
Verapamil
Mechanisms of action: calcium-channel blocker; decrease in peripheral vascular resistance, without an increase in heart
rate as a reflex response
Onset of action: within 5 min.
Duration of action: half-life between 3.5 and 7.4 hours
Specific indications: hypertension with tachycardia and contraindications to beta-blockers
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Specific contraindication: common to calcium-channel blockers
Esmolol
Mechanisms of action: beta1-selective blocker
Onset of action: maximal effect of the selected dose within 5 min. after bolus
Duration of action: 10-30 min., half-life 9 min.
Specific indications: perioperative hypertension, aortic dissection, ischemic stroke, acute coronary syndrome
Specific contraindication: pregnancy, common contraindications to beta-blockers
Metoprolol
Mechanisms of action: selective beta-blocker
Onset of action: within 5 min.
Duration of action: to 4 hours, elimination half-life 1-9 hours, average 3.5 hours
Specific indications: aortic dissection, acute coronary syndrome
Specific contraindication: pregnancy, common contraindications to beta-blockers
Labetalol
Mechanisms of action: non-selective beta-blocker, weak alpha-blocker
Onset of action: within 5-10 min.
Duration of action: 2-6 hours
Specific indications: eclampsia, any severe hypertension
Specific contraindication: common contraindications to beta-blockers
Phentolamine
Mechanisms of action: non-selective alpha-blocker
Onset of action: minutes
Duration of action: 2-4 hours
Specific indications: during surgical manipulation with phaeochromocytoma
Specific contraindication: common contraindications to alpha-blockers
Table 3. Medication for the management of hypertensive emergencies
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